Medmira Stock Company Profile

Description

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America, the Caribbean, Europe, the Asia Pacific, and internationally. The company's research is focused on specific areas of the diagnostics market, such as rapid, point-of-care, and in vitro sectors. It offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. The company also provides Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and REVEALCOVID-19, an antibody test. In addition, it offers Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics. MedMira Inc. sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. operates as a subsidiary of MedMira Holding AG.